KLOW

KLOW is a precision quad-peptide research blend combining BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg + KPV 10mg in a single sterile vial. Each component targets a distinct but complementary repair pathway, making KLOW one of the most comprehensive multi-peptide formulations available.

Key Research Areas

• BPC-157 10mg — cytoprotection, gut-brain axis repair, angiogenesis and FAK-paxillin pathway activation
• TB-500 10mg — systemic actin regulation, cell migration and soft tissue recovery
• GHK-Cu 50mg — collagen and elastin synthesis, antioxidant enzyme activation and gene expression modulation
• KPV 10mg — NF-κB inhibition, pro-inflammatory cytokine reduction and mucosal healing
• Synergistic multi-pathway approach: local repair + systemic recovery + regeneration + anti-inflammation

Mechanism of Action

KLOW combines four peptides acting on complementary pathways: BPC-157 activates FAK-paxillin and NO signalling for local repair; TB-500 sequesters G-actin for systemic cell migration; GHK-Cu activates TGF-β and collagen synthesis; KPV blocks NF-κB to suppress inflammation. Together they provide a broad-spectrum regenerative and anti-inflammatory effect.